Annual Reports in Medicinal Chemistry provides timely and critical reviews of important topics in medicinal chemistry with an emphasis on emerging topics in the biological sciences that are expected to provide the basis for entirely new future therapies. Reviews on hot topics of interest in small molecule drug discovery heavily pursued by industrial research organizationsProvides preclinical information in the context of chemical structuresKnowledgeable section editors who evaluate invited reviews for scientific rigor INDICE: A Personal Essay: My Experiences in the Pharmaceutical IndustryAdventures in Medicinal Chemistry - A Career in Drug DiscoveryNatural and Synthetic Neuroactive Steroid (NAS) Modulators of GABAA and NMDA ReceptorsDevelopment of LRRK2 Kinase Inhibitors for Parkinson's DiseaseStimulating Neurotrophin Receptors in the Treatment of Neurodegenerative DisordersSmall Molecule Modulators of GPR40 (FFA1)Recent Advances in the Development of P2Y12 Receptor Antagonists as Antiplatelet AgentsCurrent Approaches to the Treatment of Atrial FibrillationAdvances in the Discovery of Small Molecule IRAK4 InhibitorsH4 Receptor Antagonists and Their Potential Therapeutic ApplicationsUrate Crystal Deposition Disease and Gout - New Therapies for an Old Problemp53 - MDM2 and MDMX AntagonistsModulators of Atypical Protein Kinase C as Anticancer AgentsAdvancement of Cell Wall Inhibitors in Mycobacterium TuberculosisNucleosides and Nucleotides for the Treatment of Viral DiseasesAdvances in Inhibitors of Penicillin Binding Proteins and ß-lactamases as Antibacterial AgentsTumor Microenvironment as Target in Cancer TherapyNovel Screening Paradigms for the Identification of Allosteric Modulators and /or Biased Ligands for Challenging G-Protein-Coupled Receptors (GPCRs)Mer Tyrosine Kinase Receptor: Therapeutic Opportunities in Oncology, Virology and Cardiovascular IndicationsDisease Modifying Agents for the Treatment of Cystic FibrosisAdvancements in Stapled Peptide Drug Discovery and DevelopmentCytochrome P450 Enzyme Metabolites in Lead Discovery and DevelopmentCase History: ForxigaTM (Dapagliflozin), a Potent Selective SGLT2 Inhibitor for Treatment of DiabetesCase History: Kalydeco® (VX-770, Ivacaftor), a CFTR Potentiator for the Treatment of Patients with Cystic Fibrosis and the G551D-CFTR MutationCase History: XeljanzTM (Tofacitinib Citrate), A First-In-Class Janus Kinase (JAK) Inhibitor for the Treatment of Rheumatoid ArthritisNew Chemical Entities Entering Phase III Trials in 2013To Market, To Market - 2013
- ISBN: 978-0-12-800167-7
- Editorial: Academic Press
- Encuadernacion: Rústica
- Páginas: 472
- Fecha Publicación: 12/11/2014
- Nº Volúmenes: 1
- Idioma: Inglés